Darzalex (Daratumumab)

Darzalex (Daratumumab) is an innovative monoclonal antibody therapy designed for the treatment of multiple myeloma, a cancer that affects plasma cells in the bone marrow. As a targeted immunotherapy, Darzalex specifically binds to the CD38 protein, which is highly expressed on the surface of myeloma cells. This targeted action helps the body’s immune system recognize and eliminate cancer cells while providing a more precise treatment approach.

Darzalex is approved for use in various stages of multiple myeloma and may be administered as monotherapy or in combination with other anti-cancer medications, depending on the patient’s treatment needs and clinical condition. Its introduction has significantly advanced the management of multiple myeloma by improving response rates and extending progression-free survival for many patients.

Available in intravenous and subcutaneous formulations, Darzalex offers flexibility in administration and is used under the supervision of qualified healthcare professionals. Clinical studies have demonstrated its effectiveness in both newly diagnosed and relapsed or refractory multiple myeloma patients, making it an essential component of modern hematology and oncology treatment strategies.

As a leading targeted immunotherapy, Darzalex represents a major advancement in blood cancer treatment, providing healthcare providers and patients with an effective option for managing multiple myeloma and improving long-term treatment outcomes.